The biopharmaceutical and digital health sectors are undergoing a structural convergence driven by asymmetric financial pressures, shifting commercial models, and evolving regulatory frameworks. Biopharma is entering an aggressive loss of exclusivity (LOE) cycle, frequently designated the "super patent cliff," in which an estimated $200 Billion to $300 Billion in annual global branded revenues will expire between 2025 and 2030. This impending revenue contraction coincides wit

As the global healthcare sector approaches the 2026 fiscal year, the capital markets are poised for a definitive structural transformation. Following a tumultuous half-decade characterized by the exuberant highs of the Zero Interest Rate Policy (ZIRP) era and the subsequent liquidity crunch of 2022–2024, the IPO landscape has entered a phase of "Rational Exuberance." This new paradigm is defined not by the speculative fervour that drove the 2020–2021 vintage, but by a discipl